BC Week In Review | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
BC Week In Review | Jul 28, 2014
Clinical News

Breast Cancer Index regulatory update

bioMerieux’s bioTheranostics Inc. company said the New York State Department of Health approved the company’s Breast Cancer Index (BCI) to determine the risk of early and late recurrence and benefit from extended endocrine therapy in...
BC Week In Review | Jul 28, 2014
Company News

bioMerieux sales and marketing update

bioMerieux’s bioTheranostics Inc. subsidiary said U.S. healthcare provider FedMed Inc. will cover genomic tests for patients with breast cancer and metastatic cancers. bioTheranostics said that FedMed has a preferred provider network that includes more than...
BC Week In Review | Sep 16, 2013
Clinical News

Breast Cancer Index diagnostic data

Researchers at Massachusetts General Hospital and colleagues reported data from 665 postmenopausal women with estrogen receptor-positive breast cancer in a prospective comparative study showing that only the BCI predicts risk for both early (0-5 years)...
BioCentury | Jan 5, 2009
Product Development

Intermediate decision-making

Oncotype DX from Genomic Health Inc. is used in over 50% of breast cancer patients to determine if they are at risk of recurrence and thus should receive chemotherapy following surgery. The problem is what...
BC Week In Review | Dec 22, 2008
Clinical News

Theros Breast Cancer Index: Data

Data from tissue samples from 166 estrogen receptor-positive breast cancer patients showed that Theros Breast Cancer Index (BCI) reduced the number of patients classified as having an intermediate risk of recurrence by 2.5-fold vs. Oncotype...
BC Week In Review | May 7, 2007
Clinical News

Breast Cancer Gene Expression Ratio Test diagnostic data

Swedish researchers reported that the H/I ratio or HOXB13 alone can predict whether certain breast cancer patients will benefit from endocrine therapy. The study used biopsy material from 357 breast cancer patients who received either...
BC Week In Review | Dec 18, 2006
Company News

Quest Diagnostics sales and marketing update

DGX launched its Breast Cancer Gene Expression Ratio ( HOXB13:IL17BR ) test to predict the risk of disease recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer. The test is based on gene-expression profiling technology that...
Items per page:
1 - 8 of 8